Heparin and low-molecular-weight heparin

Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 45-65

  Morrow, David A ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953300142     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0408-4.50011-1     Document Type: Chapter

References (124)

1. Lee RT, Libby P The unstable atheroma. Arterioscler Thromb Vasc Biol 1997, 17:1859-1867.
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000, 36:970-1062.
3. Camerer E, Kolsto AB, Prydz H, et al. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996, 81:1-41.
4. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996, 94:3090-3097.
5. Dahlback B Blood coagulation. Lancet 2000, 355:1627-1632.
6. Weitz JI Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
7. Danielsson A, Raub E, Lindahl U, et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986, 261:15467-15473.
8. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998, 114:489S-510S.
9. Antman EM The search for replacements for unfractionated heparin. Circulation 2001, 103:2310-2314.
10. Warkentin TE, Chong BH, Greinacher A Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998, 79:1-7.
11. Deitcher SR, Carman TL Heparin-induced thrombocytopenia: Natural history, diagnosis, and management. Vasc Med 2001, 6:113-119.
12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
13. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992, 67:639-643.
14. Young E, Cosmi B, Weitz J, et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993, 70:625-630.
15. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994, 71:300-304.
16. Serra A, Esteve J, Reverter JC, et al. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. Thromb Res 1997, 87:405-410.
17. Hansen JB, Sandset PM Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy. Thromb Res 1998, 91:177-181.
18. Hansen JB, Naalsund T, Sandset PM, et al. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. Thromb Res 2000, 100:413-417.
19. Sandset PM, Bendz B, Hansen JB Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000, 30:48-56.
20. Lupu C, Poulsen E, Roquefeuil S, et al. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999, 19:2251-2262.
21. Telford AM, Wilson C Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981, 1:1225-1228.
22. Williams DO, Kirby MG, McPherson K, Phear DN Anticoagulant treatment of unstable angina. Br J Clin Pract 1986, 40:114-116.
23. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319:1105-1111.
24. Theroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88:2045-2048.
25. Cohen M, Adams PC, Hawkins L, et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol 1990, 66:1287-1292.
26. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994, 89:81-88.
27. The RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990, 336:827-830.
28. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994, 24:39-45.
29. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995, 26:313-318.
30. Neri Serneri GG, Gensini GF, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 1990, 335:615-618.
31. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996, 276:811-815.
32. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Available at: 2002. Accessed August 10, 2003. http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.
33. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995, 91:1929-1935.
34. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145.
35. Melandri G, Branzi A, Traini AM, et al. On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 1993, 71:469-471.
36. Tracy RP, Kleiman NS, Thompson B, et al. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Am Heart J 1998, 135:29-37.
37. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial. Circulation 1996, 93:870-878.
38. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987, 82:703-713.
39. Becker RC, Cannon CP, Tracy RP, et al. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J 1996, 131:421-433.
40. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993, 119:874-881.
41. Hassan WM, Flaker GC, Feutz C, et al. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: A randomized trial. J Thromb Thrombolysis 1995, 2:245-249.
42. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999, 138:313-318.
43. Becker RC, Ball SP, Eisenberg P, et al. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J 1999, 137:59-71.
44. FRISC Study Group Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC). Lancet 1996, 347:561-568.
45. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).Circulation 1997, 96:61-68.
46. The FRAXIS Study Group Comparison of two treatment durations of a low molecular weight heparin in the initial management of unstable angina of non-Q wave myocardial infarction: FRAXIS. Eur Heart J 1999, 20:1553-1562.
47. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. New Engl J Med 1997, 337:447-452.
48. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593-1601.
49. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000, 36:693-698.
50. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999, 100:1602-1608.
51. Antman EM, Cohen M, McCabe C, et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002, 23:308-314.
52. Fareed J, Jeske W, Hoppensteadt D, et al. Low-molecular-weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 1998, 82:3L-10L.
53. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000, 355:1936-1942.
54. Michalis LK, Papamichail N, Katsouras C, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) [abstract]. J Am Coll Cardiol 2001, 365a.
55. Turpie AG, Gallus AS, Hoek JA A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619-625.
56. Ferguson JJ Meeting Highlights: American Heart Association Scientific Sessions 2001. Circulation 2002, 105:e37-e41.
57. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998, 97:1702-1707.
58. FRISC II Investigators Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999, 354:701-707.
59. Lindahl B, Venge P, Wallentin L Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997, 29:43-48.
60. Morrow DA, Antman EM, Tanasijevic J, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI 11B sub-study. J Am Coll Cardiol 2000, 36:1812-1817.
61. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000, 284:835-842.
62. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J 2002, 144:615-624.
63. Fox KAA, Antman EM, Cohen M Are treatment effects of enoxaparin (low-molecular weight heparin) more marked in those undergoing percutaneous intervention: Results of the ESSENCE/ TIMI 11B? [abstract]. Eur Heart J 2000, 21:3267A.
64. FRISC II Investigators Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999, 354:708-715.
65. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996, 28:1437-1443.
66. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999, 84:1391-1395.
67. Young JJ, Kereiakes DJ, Grines CL Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000, 12(E):E14-E18.
68. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT). Lancet 1998, 352:87-92.
69. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001, 13:272-278.
70. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of Concomitant Therapy with Eptifibatide and Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention-Results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin Study. J Am Coll Cardiol 2003, 41:20-25.
71. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002, 40:1943-1950.
72. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001, 141:348-352.
73. Martin JL, Fry ETA, Serano A Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI Study. Eur Heart J 2001, 22:14. (Abstr Suppl).
74. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001, 103:658-663.
75. Ferguson JJ Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invasive Cardiol 2000, 12(E):E10-E13.
76. Ferguson JJ, 3rd: NICE-3 Preliminary Results. In: 22nd Congress of the European Society of Cardiology, 2000; Amsterdam, 2000.
77. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003, 42:1132-1139.
78. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999, 71:273-281.
79. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin. The ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002, 144:470-477.
80. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003, 107:238-244.
81. Blazing MA, De Lemos JA, Dyke CK, et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001, 142:211-217.
82. SoRelle R Late-breaking trials from the 52nd scientific sessions of the American College of Cardiology. Circulation 2003, 107:e9024.
83. Simoons ML Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001, 357:1915-1924.
84. The SYNERGY trial Study design and rationale. Am Heart J 2002, 143:952-960.
85. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials. BMJ 1996, 313:652-659.
86. Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997, 336:847-860.
87. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999, 100:1016-1030.
88. O'Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 1994, 23:11-18.
89. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992, 67:122-128.
90. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990, 66:1412-1417.
91. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 1990, 323:1433-1437.
92. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989, 79:281-286.
93. Col J Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction: Results of a double-blind randomized study (OSIRIS). Circulation 1992, 86(I):259.
94. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615-1622.
95. ISIS (International Studies of Infarct Survival) pilot study investigators Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987, 8:634-642.
96. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989, 2:182-186.
97. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990, 336:65-71.
98. The International Study Group In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990, 336:71-75.
99. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992, 339:753-770.
100. Ridker PM, Hebert PR, Fuster V, et al. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?. Lancet 1993, 341:1574-1577.
101. The GUSTO investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:673-682.
102. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996, 77:551-556.
103. The LATE Study Group Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993, 342:759-766.
104. GUSTO III Investigators A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III). N Engl J Med 1997, 337:1118-1123.
105. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT) Investigators Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999, 354:716-722.
106. Arnout J, Simoons M, de Bono D, et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992, 20:513-519.
107. Giugliano RP, McCabe CH, Antman EM, et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001, 141:742-750.
108. Antman EM Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994, 90:1624-1630.
109. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637.
110. Sane DC, Califf RM, Topol EJ, et al. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989, 111:1010-1022.
111. Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997, 95:2508-2516.
112. Krumholz HM, Hennen J, Ridker PM, et al. Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly. J Am Coll Cardiol 1998, 31:973-979.
113. Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 1991, 83:1534-1542.
114. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction-a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999, 33:627-633.
115. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001, 104:648-652.
116. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002, 105:1642-1649.
117. Simoons M, Krzeminska-Pakula M, Alonso A, et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI- SK study. Eur Heart J 2002, 23:1282.
118. Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J 2003, 24:897-908.
119. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997, 30:962-969.
120. Baird SH, Menown IB, McBride SJ, et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002, 23:627-632.
121. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605-613.
122. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135-142.
123. White H Further evidence that antithrombotic therapy is beneficial with streptokinase: Improved early ST resolution and late patency with enoxaparin. Eur Heart J 2002, 23:1233.
124. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol 2003, 42:1348-1356.